Aridis Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Aridis Pharmaceuticals

01/04/2022 14:26

* Aridis Pharmaceuticals Inc  ARDS.OQ  reported a quarterly
adjusted loss of 92 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for a loss of 41 cents per share.
    * Revenue was $570.00 thousand​;  analysts expected $1.90
million. 
    * Aridis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 92 cents​.
    * The mean earnings estimate of analysts had risen by
about 23% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aridis Pharmaceuticals Inc shares had held steady so far
this
quarter and lost 24.5% so far this year.
    * The company reported a quarterly loss of $13.37 million.
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated April 1 at 01:25 p.m.  ​All
figures in US dollars unless otherwise stated